Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNAR: Vyzulta vs Timolol in Glaucoma or Ocular Hypertension
NCT01749930Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Jan 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of latanoprostene bunod in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Bausch + Lomb. Primary endpoint: Mean Intraocular Pressure at Month 3. Started Jan 2013; status: completed.
02
Drugs
latanoprostene bunod
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT01749930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01749930.